Skip to content
Connect Career

Explore Our Comprehensive List of CBmed Publications

CBmed Publications

Follow the link to see a full list of publications (co-)authored by CBmed employees and affiliates. Take your time and scroll through that impressing collection of multidisciplinary knowledge or check out some featured publications in the list below.

All CBmed publications on PubMed

Featured Publications

Reviewed Papers Technologies Year

Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities – a Narrative Review

This review synthesizes current evidence on the role of the perioperative gut microbiome in gastrointestinal cancer surgery and its association with postoperative complications, including infections and anastomotic leakage. It critically evaluates microbiome‑targeted interventions, highlighting inconsistencies and gaps resulting from heterogeneous study designs and non‑standardized protocols. Finally, it outlines future directions, proposing multi‑omics–driven, personalized perioperative strategies to improve recovery and reduce complication risk of gastrointestinal cancer surgery.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/41895157/
Microbiome Research
2026

The beneficial effect of a multispecies probiotic intervention on quality of sleep: a randomized, double-blinded, placebo-controlled study.

Sleep is essential for health, cognitive function, and quality of life. Evidence suggests the gut microbiome helps regulate sleep duration and quality, and that gut dysbiosis and poor sleep may reinforce each other. In “The beneficial effect of a multispecies probiotic intervention on quality of sleep – a randomized, double-blind, placebo-controlled study”, we evaluated a multispecies probiotic’s effects on sleep quality, stress markers, and microbiome composition. Although microbiome changes and perceived stress were minimal, the intervention significantly improved sleep quality, particularly sleep efficiency and sleep latency.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/41637999/
Microbiome Research
2026

Drug screening reveals differential drug response in primary and metastatic clear cell sarcoma

This study reports differential drug responses between primary and metastatic clear cell sarcoma using drug screening approaches. The findings emphasize biological heterogeneity between tumor sites. Technologies used at CBmed: drug screening and cell culture.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/41232594/
Ex Vivo Compound Screening, Core Technologies
2026

Nitrogen recycling by the gut microbiome in sarcopenia

The study looked at whether gut bacteria can “recycle” nitrogen in people with liver cirrhosis—an effect seen in some animals that helps preserve muscle—and compared patients with and without sarcopenia (muscle loss). We found that patients with sarcopenia had a lower predicted abundance of microbial urease (an enzyme linked to nitrogen recycling), and that common medications such as proton pump inhibitors and beta-blockers were associated with differences in this urease signal. Overall, the findings suggest the gut microbiome’s nitrogen-handling capacity may be linked to muscle health in cirrhosis and could be a future target for supportive therapies.

Follow this link for more: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1698437/full
Microbiome Research
2026

An observational study on the effect of L-ornithine-L-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study.

Discover how a common liver medication could do more than just lower ammonia! In this study, patients with liver cirrhosis who took L-ornithine-L-aspartate (LOLA) for 12 weeks experienced a boost in energy and vitality, and those with high ammonia levels even stopped losing muscle mass. While LOLA didn’t dramatically change the gut microbiome, it showed promise as a supportive treatment to improve quality of life and muscle health for people living with cirrhosis.

Follow this link for more: https://www.sciencedirect.com/science/article/pii/S0261561425003048?via%3Dihub
Microbiome Research
2026

Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges

This review summarizes current approaches to ex vivo drug screening on patient derived tumor material. It also discusses unresolved challenges limiting broader clinical implementation. Technologies used at CBmed: drug screening and cell culture and advanced data analysis.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/41475298/
Ex Vivo Compound Screening, Core Technologies, Data Science
2025

T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation – An Observational Cohort Study

This observational cohort study shows that T cell activation marker HLA DR reflects tacrolimus associated immunosuppression. HLA DR levels further correlate with BK viremia risk after kidney transplantation. Technology used at CBmed: multi-parameter FACS analysis.

Follow this link for more: https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14443/full
Core Technologies
2025

Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)

This paper describes the study protocol for a clinical trial using ex vivo drug screening to personalize targeted therapies for glioblastoma patients. The trial aims to integrate functional testing into therapeutic decision‑making. Technologies used at CBmed: drug screening and cell culture facilities.

Follow this link for more: https://academic.oup.com/noa/article/7/1/vdaf056/8058931
Ex Vivo Compound Screening, Core Technologies
2025

Investigation of nanostructured lipid carriers for fast intracellular localization screening using the Echo liquid handler

This study investigates nanostructured lipid carriers for rapid intracellular localization screening. The work employs automated liquid handling to support high‑throughput analysis. Technologies used at CBmed: drug screening, cell culture and live cell imaging and advanced data analysis/ data science.

Follow this link for more: https://www.sciencedirect.com/science/article/pii/S0378517324009323
Ex Vivo Compound Screening, Core Technologies, Data Science
2024

Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study

This randomized pilot study investigates how severe COVID‑19 infection alters the gut–lung axis. It further explores whether probiotic intervention can modulate these post‑infection alterations. Technology used at CBmed: multi-parameter FACS analysis.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/39599626/
Microbiome, Core Technologies
2024

Tumor Board Visualization: Integrating Clinical and Laboratory Insights

This paper presents a visualization approach for tumor boards integrating clinical and laboratory data. The work aims to improve interdisciplinary interpretation and decision support. Technologies used at CBmed: multi-parameter FACS analysis and multi-parameter immunohistochemistry and advanced data analysis/ data science.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/39176553/
Data Science, Core Technologies
2024

Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis

This study characterizes inflammatory mediators and metabolites in interstitial fluid before and after dupilumab therapy in atopic dermatitis. Dermal open flow microperfusion is used for longitudinal profiling. Technologies used at CBmed: multi-parameter FACS analysis and advanced data analysis / data science.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/38986055/
Core Technologies, Data Science
2024

Atraumatic access to human glioblastoma in a xenograft animal model by cerebral open flow microperfusion

This methodological paper describes an atraumatic technique to access human glioblastoma tissue in xenograft models. The approach enables longitudinal sampling using open flow microperfusion. Technologies used at CBmed: drug screening and cell culture and multi-parameter immunohistochemistry.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/37217139/
Ex Vivo Compound Screening, Core Technologies
2023

Alterations in the Kynurenine–Tryptophan Pathway and Lipid Dysregulation Are Preserved Features of COVID-19 in Hemodialysis

This study finds persistent alterations in the kynurenine–tryptophan pathway and lipid metabolism in hemodialysis patients after COVID 19. The data suggest long lasting metabolic dysregulation. Technologies used at CBmed: multi-parameter FACS analysis, metabolomics and advanced data analysis / data science.

Follow this link for more: https://www.mdpi.com/1422-0067/23/22/14089
Core Technologies, Data Science
2022

Cell2Grid: an efficient, spatial, and convolutional neural network-ready representation of cell segmentation data

This paper introduces Cell2Grid, a spatial and CNN ready representation for cell segmentation data. The method facilitates deep learning based image analysis. Technologies used at CBmed: multi-parameter immunohistochemistry and advanced data analysis / data science.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/36466076/
Data Science, Core Technologies
2022

To Waste or Not to Waste: Questioning Potential Health Risks of Micro- and Nanoplastics with a Focus on Their Ingestion and Potential Carcinogenicity

We’re all exposed to tiny plastic particles — often without even knowing it. They’re in the water we drink, the food we eat, and the air we breathe. But what does that mean for our health? The review article, “To Waste or Not to Waste,” was the entry point to explore micro- and nanoplastics, how they enter our bodies, and whether they could pose risks such as cancer. An article that provides first hints to a big question that affects us all.

Follow this link for more: https://link.springer.com/article/10.1007/s12403-022-00470-8
Microplastics & Health
2022

The effect of spermidine on autoimmunity and beta cell function in NOD mice

This experimental study examines the effects of spermidine on autoimmunity and beta cell function in NOD mice. The results link polyamine metabolism to autoimmune diabetes mechanisms. Technologies used at CBmed: multi-parameter FACS analysis and multi-parameter immunohistochemistry

Follow this link for more: https://www.nature.com/articles/s41598-022-08168-2
Core Technologies
2022

Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19

This study suggests that chronic inflammation may protect hemodialysis patients from severe COVID 19. The findings challenge assumptions about immunological vulnerability in this population. Technology used at CBmed: multi-parameter FACS analysis.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/35265078/
Core Technologies
2022

B Cell Composition Is Altered After Kidney Transplantation and Transitional B Cells Correlate With SARS-CoV-2 Vaccination Response

This study shows that B‑cell subsets change following kidney transplantation. Transitional B cells are correlated with the immune response to SARS‑CoV‑2 vaccination. Technology used at CBmed: multi-parameter FACS analysis.

Follow this link for more: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.818882/full
Core Technologies
2022

T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study

This clinico pathological study shows that regulatory T cells predict clinical outcome in soft tissue sarcoma patients. Immune infiltration is linked to prognosis. Technologies used at CBmed: multi-parameter immunohistochemistry and advanced data analysis / data science.

Follow this link for more: https://www.nature.com/articles/s41416-021-01456-0
Data Science, Core Technologies
2021

Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans

This clinical study reports that alternate‑day fasting improves physiological and molecular markers associated with aging in healthy, non‑obese adults. The work links dietary intervention to measurable systemic and molecular changes relevant to aging biology. Technology used at CBmed: mult-parameter FACS analysis.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/31471173/
Core Technologies
2019

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML

This study reports that high GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34 positive AML. The findings link surface markers to stemness features. Technologies used at CBmed: multi-parameter FACS analysis and advanced data analysis / data science.

Follow this link for more: https://pubmed.ncbi.nlm.nih.gov/30848055/
Core Technologies, Data Science
2019

Crosstalk between Stem and Progenitor Cellular Mediators with Special Emphasis on Vasculogenesis

This review discusses interactions between stem and progenitor cells with a focus on mechanisms driving vasculogenesis. It highlights cellular mediators relevant to vascular development and regeneration. Technologies used at CBmed: multi-parameter immune-histochemistriy and advanced data analysis.

Follow this link for more: https://pmc.ncbi.nlm.nih.gov/articles/PMC5473070/
Core Technologies, Data Science
2017

Scientific Posters